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An experimental approach is described for determining protein-small molecule non-covalent
ligand binding sites and protein conformational changes induced by ligand binding. The
methodology utilizes time resolved limited proteolysis and the high throughput analysis
capability of MALDI TOF MS to determine the binding site in a tetanus toxin C-fragment (51
kDa)-doxorubicin (543 Da) non-covalent complex. Comparing relative ion abundances of
peptides released from the time resolved limited proteolysis of tetanus toxin C-fragment
(TetC) and the TetC-doxorubicin complex every 10 min from 10 to 120 min of digestion
revealed that the binding of doxorubicin induced a significant change in surface topology of
TetC. Four of the twenty-nine peptides observed by MALDI MS, including amino acids
351–360, 299–304, 305–311 and 312–316, had a lower abundance in the TetC-doxorubicin
complex relative to TetC from 10 to 100 min of digestion. A decrease in ion abundance suggests
doxorubicin obstructs the access of the protease to one or both termini of these peptides,
identifying doxorubicin binding site(s). Conversely, five peptide ions, including amino acids
335–350, 364–375, 364–376, 281–298, and 316–328, all had a greater abundance in the digest of
the complex, indicating an increase in accessibility to these sites. These five peptides flank
regions of decreased ion abundance, suggesting that doxorubicin not only binds to the surface,
but also induces a conformational change in TetC. (J Am Soc Mass Spectrom 2003, 14,
460–470) © 2003 American Society for Mass Spectrometry
Non-covalent complexes formed between bi-omolecules such as proteins, small molecules,DNA, RNA, and metal ions play a central role
in many important biochemical processes such as gene
transcription, cell signaling, and ion transport. Under-
standing molecular dynamics and the structural aspects
of non-covalent interactions is also at the heart of drug
design where therapeutic molecules work by blocking
or modifying the biological function of proteins, DNA
or RNA. Experimental design to probe biologically
relevant non-covalent complexes must consider several
aspects of complex formation including methods for (1)
screening and identifying components of a complex, (2)
mapping the interaction interface, and (3) measuring
consequences of complex formation on secondary, ter-
tiary, or quaternary structure.
During the last decade, electrospray ionization (ESI)
and matrix assisted laser desorption ionization
(MALDI) mass spectrometry (MS) have become viable
techniques for measuring the three aforementioned
aspects of non-covalently bound macromolecular com-
plexes. ESI, in particular, has emerged as the ionization
method of choice for detection of intact non-covalent
complexes [1–5] because it involves molecular ioniza-
tion directly from aqueous-based solutions designed to
mimic physiological conditions. ESI gently evaporates
the solvent, leaving solution based macromolecular
complexes intact while transforming the complexes into
gas-phase ions. For example, Wigger et al. [5] combined
ESI FT-ICR MS with stored-waveform inverse Fourier
transform and IR multiphoton dissociation to detect
intact protein-ligand complexes from a solution con-
taining a protein and a combinatorial library of 324
peptides. Following detection of the ligand free protein
and intact non-covalent complexes, selective dissocia-
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tion via gas-phase methods identified the ligand(s)
bound to the protein.
Ancillary techniques involving immobilized proteins
[6], pulsed ultrafiltration [7], affinity chromatography
[8, 9] or size exclusion chromatography [10, 11] as a
means for isolating members of molecular complexes
prior to MS analysis have also been developed to screen
for potential protein-ligand complexes. Unlike the pre-
vious examples, these techniques do not rely on ioniza-
tion and detection of intact complexes. For example,
Cancilla and co-workers [6] developed an immobilized
enzyme MS method to screen for potential small mole-
cule inhibitors of pepsin and glutathione S-transferase
from a combinatorial library consisting of 17–20 li-
gands. In this study, MS was performed on a chosen
molecular library prior to and following incubation
with immobilized enzymes. Differences in relative ion
abundances of the library molecules prior to and after
incubation not only identified inhibitors that bound to
the enzyme, but also reflected the affinity of the mole-
cules for the protein. Size exclusion gel filtration chro-
matography offers another means of identifying pro-
tein-ligand complexes by allowing large proteins and
protein-ligand complexes to pass through a column
while retaining lower molecular weight compounds.
ESI MS performed under denaturing conditions, of the
filtrate identified ligands bound to the protein [10, 11].
The methods described above for screening and identi-
fying protein-ligand complexes only determine whether
a given ligand binds to a protein, but does little to
indicate binding sites or protein structural changes
induced by complex formation.
Recently, covalent protein crosslinking coupled to
MS analysis has been used to obtain low resolution
tertiary structural information of proteins via intramo-
lecular crosslinking [12] and to determine binding sites
in protein-ligand and protein-protein complexes via
intermolecular crosslinking [13–17]. Shapiro et al. [17]
defined the ganglioside binding region of tetanus toxin
C-fragment by covalently crosslinking ganglioside
GD1b modified with a radio-labeled photoaffinity tag
on the terminal sialic acid. After covalently attaching
the modified ganglioside to TetC, the complex was
subjected to proteolysis and the resulting fragments
separated on SDS-PAGE gels. In-gel digestion followed
by MALDI MS of the band containing the radiolabeled
photoaffinity tag identified the C-terminal 34 amino
acids of the 452 amino acid protein as the GD1 binding
site. Although covalent crosslinking may provide useful
information to indicate binding sites by formation of
covalent bonds, the true dynamic nature of protein
structural changes induced by complex formation are
difficult to probe. For example, the photoaffinity tag
only identified the point at which the one labeled sialic
acid interacts with protein and does not address possi-
ble interactions with the remainder of the ganglioside
structure.
NMR and X-ray crystallography are the primary
analytical tools used to obtain atomic level structural
information relating to protein-ligand binding sites and
protein conformation changes induced by complex for-
mation. Recently, however, limited proteolysis coupled
to MS has been shown to provide important structural
information of solution-phase non-covalent interac-
tions, albeit low resolution, by determining structural
intermediates in protein folding studies [18, 19] and
mapping interfaces in protein-protein [20–24] and pro-
tein-DNA complexes [25]. Limited proteolysis relies on
the ability of a protein to interact with the structural
motif surrounding a protease’s active site [26], i.e., a
protease cannot cleave a protein if a cleavable site is
protected by a protein’s tertiary structure or by complex
formation with another molecule. For example, Cohen
et al. [25] utilized limited proteolysis and MALDI MS to
determine the interaction interface between the tran-
scription factor Max and a Max-specific DNA sequence.
Using peptide maps generated with MALDI MS, they
observed a significant decrease in proteolysis rates and
changes in proteolysis patterns in the Max-DNA com-
plex relative to Max alone. The difference in peptide
maps and digestion rates were used to infer the inter-
facial region of the complex and to suggest protein
conformational changes. Limited proteolysis and
MALDI MS analysis were also used by Kriwacki et al.
[20] to ascertain the binding sites in a protein-protein
complex. In this example, the authors interpreted the
absence of peptide ions in the mass spectrum of the
protein-protein complex relative to free protein to indi-
cate the region of binding. However, based on limited
proteolysis and MS experiments alone, it was difficult
to unambiguously discern the binding interface of the
protein-protein complex versus potential conformation
changes induced by complex formation. To find bind-
ing sites and detect conformation changes, the above
examples exploit significant changes in protein folding
or high affinity complexes with large interfaces to
completely block a protease’s access to specific amino
acids. To date, limited proteolysis and MS methods
have not been used to understand structural impacts of
protein-small molecule ligand non-covalent complex
formation.
Experimental screening of small molecules that bind
to target proteins while obtaining detailed structural
information about binding sites and protein tertiary
structure changes is critical to the development of
therapeutic agents as well as development of chemical
sensors based on molecular recognition principles. In
this paper, we demonstrate the use of time resolved
limited proteolysis of the non-covalently bound TetC-
doxorubicin complex using MALDI TOF MS to deter-
mine doxorubicin binding site(s). MALDI TOF MS was
chosen as the analysis technique over ESI or LC/MS
because of the high sample throughput and automation
necessary to collect statistically relevant data. In addi-
tion, we utilized ESI MS to demonstrate TetC-doxoru-
bicin non-covalent complex formation at solution con-
ditions optimized for limited proteolysis.
Tetanus neurotoxin (TeNT) is a 150 kDa clostridial
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toxin consisting of 50 kDa and 100 kDa polypeptide
chains linked by a disulfide bond. The heavy chain is
known to bind to presynaptic neuronal cells followed
by light chain penetration into the cell which inhibits
neurotransmitter release. The 51 kDa carboxy-terminal
domain of the heavy chain, TetC, has been shown to be
the binding subunit [27] to gangliosides on the neuronal
cell surface [28]. The first step to develop inhibitors of
TeNT function or to develop chemical sensors based on
recognition principles is to find molecules that bind to
the protein and inhibit binding to gangliosides on the
cell surface. This requires an understanding of protein
structure and protein-ligand binding sites. Doxorubicin
has been computationally predicted and experimentally
shown to bind TetC [29, 30]. Herein, we implement time
resolved limited proteolysis of the non-covalently
bound TetC-doxorubicin complex, using MALDI TOF
MS analysis, to determine doxorubicin binding site(s).
In addition to binding site determination, these meth-
ods also suggest the ability to address protein dynamics
by determining conformational changes induced by
ligand binding.
Experimental
Limited Proteolysis
Time resolved limited proteolysis of TetC and TetC-
doxorubicin were performed using sequencing grade
modified trypsin (Promega, Madison, WI) in a 300:1
protein:enzyme wt:wt ratio. TetC (4 M) and a TetC:
doxorubicin mixture (4:40 M) in 10 mM ammonium
acetate (pH 7.7) were digested simultaneously. A 1 L
aliquot of each digest was extracted every 10 min up to
120 min, followed by every 60 min up to 12 h. To
quench trypsin activity, each 1 L aliquot was added to
6 L of 0.1% TFA (pH 1.9).
MALDI MS Analysis
MALDI mass spectra were acquired on a PerSeptive
Biosystems (Framingham, MA) Voyager DE-STR TOF
mass spectrometer equipped with a nitrogen laser (337
nm). Mass spectra were obtained in positive ion and
reflectron mode with an acceleration voltage of 25 kV,
grid voltage of 64.8%, and delay time of 275 ns and
averaged over 100 laser shots. Each spectrum was
internally calibrated with TetC tryptic fragment ions at
m/z 2344.1131 and 1135.5132 providing mass measure-
ment accuracies of approximately 10 ppm across the
600–5500 Da mass range.
For each time point in the time resolved limited
proteolysis, ten total mass spectra were acquired, five
from two different sample spots resulting in 440 total
mass spectra, 220 from the TetC and 220 from the
TetC-doxorubicin digests. Absolute ion abundances of
the tryptic fragments generated by MALDI, as deter-
mined by peak area of the monoisotopic peak were, on
average, 20% (see sample preparation below). Due to
the inherent inconsistency in ionization and ion yield in
MALDI, the data is represented in percent relative
abundance. To calculate an average relative ion abun-
dance and associated error with this measurement, a
total ion current for each mass spectrum (m/z 600–5500)
was determined by summing monoisotopic peak areas
for each peptide ion observed. Peak areas of each ion
were then divided by the total ion current, providing a
percent relative ion abundance of each ion in each mass
spectrum. The percent relative abundance was aver-
aged for the 10 spectra collected at each time point in
the limited proteolysis.
Ion yields vary significantly from shot to shot in
MALDI; therefore, uniform and reproducible MALDI
sample preparation techniques are critical to the success
and reproducibility of the limited proteolysis experi-
ments. The typical dried droplet method of co-deposit-
ing analyte and matrix from a 50% organic solution
onto a metal surface causes inhomogeneous and irreg-
ular crystallization resulting in analyte segregation and
erratic ion yields even within the same sample spot [31].
Several MALDI sample deposition methods have been
developed to promote uniform analyte deposition on a
metal surface [32–34]. We utilized a MALDI sample
preparation system outlined by Edmondson and Rus-
sell [33]. Briefly, in our study, 5 L of a saturated
solution of -cyano-4-hydroxycinnamic acid in metha-
nol was deposited on a flat stainless steel MALDI
sample plate. Fast evaporation of methanol deposited a
uniform matrix crystal seed layer. 3 L of 5mg/mL
-cyano-4-hydroxycinnmaic acid in methanol was com-
bined with the 1 L of tryptic digest and 6 L of 0.1%
TFA and 0.5 L of this mixture was deposited on the
matrix crystal bed. To assure that the ion yield and ion
distribution is representative of the entire sample spot,
the laser was rastored across the sample spot, averaging
100 laser shots per spectrum. Although the absolute ion
abundances acquired from this homogeneous sample
deposition was on average 20%, the relative ion yield
and ion distribution across the entire spot was consis-
tent.
Ion yields in MALDI can also be influenced by the
molecular composition of the sample. To verify that
uncomplexed doxorubicin was not responsible for ion
suppression/enhancement effects in determining rela-
tive ion abundances, a control experiment was per-
formed. TetC was digested as described above and
doxorubicin was added post digestion in a TetC:doxo-
rubicin 1:10 molar ratio. Relative peptide ion abun-
dances were calculated for the TetC digest and the TetC
digest-doxorubicin mixture. At the early stages of pro-
teolysis, 10 and 20 min, doxorubicin had a suppression
effect on the absolute abundances of all ions observed,
but relative ion abundances in the sample containing
doxorubicin were within the experimental error of
those in the control sample. As more tryptic peptides
were liberated from TetC at longer digestion times,
doxorubicin had less impact on ion suppression. Ion
enhancement due to the presence of doxorubicin was
462 SHIELDS ET AL. J Am Soc Mass Spectrom 2003, 14, 460–470
never observed. Therefore, the relative ion abundances
determined in the limited proteolysis studies of TetC
and TetC-doxorubicin reflects changes in digestion
rates in solution, and not ion suppression/enhancement
effects of MALDI.
ESI MS
ESI TOF MS (LCT, Micromass, Manchester, UK) meth-
ods were utilized to detect non-covalent complex for-
mation between TetC and doxorubicin under sample
conditions optimized for binding site determination by
limited proteolysis. Similar ESI TOF MS experiments on
TetC were performed by Lightstone et al. [29], but have
been reproduced and presented here to address struc-
tural aspects of non-covalent complex formation as
detected by ESI MS. Briefly, lyophilized TetC (Roche
Molecular Biochemicals, Indianapolis, IN) was reconsti-
tuted in 10 mM ammonium acetate at pH 7.7 to a
concentration of 38 M and doxorubicin (Sigma-Al-
drich Chemical Co.; St. Louis, MO) to a concentration of
0.9 mM. A final mixture containing 10 M TetC and 100
M doxorubicin was allowed to equilibrate at room
temperature for 30 min prior to ESI analysis. Instrument
conditions consisted of 3000 V applied to the needle and
a cone voltage that was varied from 80–120 V with an
infusion rate of 3 L/min. Mass spectra were averaged
over 50 scans. Optimum cone voltages for observing
complex formation were 90–100 V and complete com-
plex dissociation was observed at 120 V.
Results and Discussion
Understanding where small molecules bind to proteins
and how the binding affects the protein structure is the
key to the development of high affinity ligands for the
purpose of immunoassay detection technologies or
drug discovery. NMR and X-ray crystallography have
been the primary analytical tools used to obtain de-
tailed atomic-level characterization of protein-ligand
interactions. Computational modeling using homology
[35], docking or solvation [36], or grid [37] based
methods is also playing a key role in identifying regions
on proteins that may serve as a binding site as well as
predicting what molecules will bind to that site. In this
study, we have developed a high throughput time
resolved limited proteolysis MALDI MS method to
confirm doxorubicin’s computationally predicted bind-
ing site to TetC [29]. TetC-doxorubicin is a weakly
bound non-covalent complex with an experimentally
determined dissociation constant of 9.4 M [29]. Since
doxorubicin (543 Da) is not likely, nor predicted, to
induce a global conformation change in TetC (51.7 kDa)
and the interaction interface is small, meticulous exper-
imental design and data interpretation make time re-
solved limited proteolysis unique to the study of
weakly bound protein-small molecule non-covalent
complexes.
Immobilized enzyme mass spectrometry techniques
for screening molecular libraries of potential small
molecule inhibitors to enzymes [6] utilized excess en-
zyme relative to the total inhibitor molar concentration
to be certain there are plenty of protein sites available
for binding. The limited proteolysis experiments re-
quire the reverse scenario, molar excess ligand, to be
certain that as many binding sites as possible are
occupied (i.e., no excess ligand-free protein in solution)
without forcing non-specific interactions to occur. Ini-
tially, molar ratios were varied from 1:1 to 1:50 TetC:
doxorubicin. At a 1:1 molar ratio there was no quanti-
tative difference in the proteolytic fragment ion
abundances, as measured by MALDI MS, observed
from the TetC relative to the TetC-doxorubicin com-
plex. This was likely due to a large amount of unbound
TetC in the TetC-doxorubicin solution. Conversely, at a
1:50 TetC:doxorubicin ratio there was a significant
change in the proteolysis patterns suggesting that when
present in great excess, doxorubicin interacted non-
specifically with the surface of TetC or generally inter-
fered with the protease’s access to TetC. Changes in the
rate of proteolysis were first observed at a 1:10 TetC:
doxorubicin molar ratio, and we chose this molar ratio
to develop the time resolved limited proteolysis meth-
ods.
NMR [30] and ESI MS [29] ligand screening tech-
niques have previously demonstrated that doxorubicin
does bind to TetC, but could not determine binding
sites. In particular, titration experiments utilizing ESI
MS experiments were used to determine TetC-doxoru-
bicin dissociation constants [29], but have been repro-
Figure 1. ESI-TOF mass spectrum of (a) TetC and (b) a solution
containing a 1:10 molar ratio of TetC:doxorubicin. The peaks
labeled *1 and *2 in (b) correspond to [TetC  1doxorubicin 
nH]n and [TetC 2doxorubicin nH]n, respectively. Although
binding of one, two, and perhaps three doxorubicin molecules to
TetC is observed, the overall charge state distribution is conserved
in the mass spectrum of the non-covalent complex.
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duced here to simply demonstrate ligand binding at the
same solution conditions optimized for limited proteol-
ysis experiments. Figure 1 contains the ESI TOF mass
spectrum of TetC (Figure 1a) and TetC-doxorubicin
complex(es) in a 1:10 molar ratio (Figure 1b). In the ESI
mass spectrum revealing TetC-doxorubicin complex
formation, adducts to TetC correspond to the binding of
one (peaks labeled with *1) and two (peaks labeled with
*2) doxorubicin molecules. If the assumption is made
that gas-phase ESI-MS mimics solution-phase behavior,
then this binding stoichiometry, at a 1:10 TetC:doxoru-
bicin molar ratio, suggests multiple doxorubicin bind-
ing sites and/or non-specific binding. However, it is
difficult to quantitate the binding stoichiometry by ESI
MS [38] in this example because protein denaturization
due to solvent evaporation in the electrospray process
in combination with excess ligand can affect protein-
ligand binding stabilities, binding sites and binding
stoichiometry. Others have noted the inability to di-
rectly correlate energetics of gas-phase to solution-
phase binding in protein-ligand complexes. Wu et al.
[4], Wigger et al. [5], and Rogniaux [43] et al. observed
that gas-phase stabilities of protein-ligand complexes
reflect polar and electrostatic interactions in contrast to
solution based stabilities which are dominated by hy-
drophobic interactions, signifying the importance of
understanding solvation effects in non-covalent com-
plex formation when designing MS experiments. More-
over, the ESI experiments presented here were not
intended to determine ligand binding specificity or
non-specificity, but simply to demonstrate binding. To
determine ligand binding specificity by ESI MS meth-
ods several experimental conditions would need opti-
mization including cone voltages, ESI source tempera-
tures, flow rates (e.g.; nanospray), solution ionic
strength, pH, and ligand and protein titration experi-
ments.
Solution based NMR experiments used to detect
doxorubicin binding to TetC, a 1:1 protein:ligand molar
ratio was not sufficient to detect ligand binding and
optimal molar ratios were 1:16 to 1:22 [30]. In ligand
competition experiments using NMR, another ligand
predicted to bind to the same site as doxorubicin,
3'-sialyllactose, displaced doxorubicin from TetC sug-
gesting a specific interaction. However, the NMR ex-
periment, as performed, could not rule out additional,
low abundant non-specific doxorubicin binding. In a
similar manner, the limited proteolysis studies are used
to probe solution-phase binding and excess ligand was
required to observe changes in the rates of protein
digestion when coupled to MALDI MS analysis.
Independent of the energetics of gas-phase and so-
lution-phase non-covalent complex formation, informa-
tion about the conformation of TetC can also be ascer-
tained from the charge state distributions in the ESI
mass spectra of Figure 1. Protein charge state distribu-
tions in ESI have been shown to be dependent on
solution conditions such as pH and organic content
where changes in the charge state distribution reflects
denatured versus globular protein structure [39–42]. In
regards to protein-ligand non-covalent complexes, Pra-
manik et al. [2] observed a shift to a lower charge state
distribution (13 to 9) of the ras protein-guanosine
diphosphate (GDP) complex at a pH of 4.7 relative to a
10 to 8 charge state distribution of the complex at
pH 5.2. At both pHs, the ras-GDP complex remained
intact even though the charge state distribution sug-
gested a slight denaturation of the protein. Based on the
concept that changes in charge state distributions may
reflect protein conformational changes in solution, the
absence of a shift in the charge state distribution of the
TetC-doxorubicin complex relative to TetC, implies that
complex formation did not have a significant impact on
the global structure of TetC. Thus, the ESI MS data
Figure 2. 452 amino acid sequence of TetC. The underlined amino acids are observed in the MALDI
TOF mass spectrum of the tryptic digest of TetC and the TetC-doxorubicin complex by 120 min.
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suggests doxorubicin binds to TetC with an insignifi-
cant amount of tertiary structure change to affect the
charge state distribution, but does not provide any
information as to the binding site(s).
Since doxorubicin is predicted to bind to the surface
of TetC and not induce a global conformation change,
an understanding of the surface topology of TetC
relative to the TetC-doxorubcin complex is imperative
in order to determine binding site(s) and this is accom-
plished with time resolved limited proteolysis. Trypsin
was selected as the protease because there are several
lysine and arginine residues in the predicted doxorubi-
cin binding region and a 300:1 TetC:trypsin wt:wt ratio
provided a proteolysis rate that was measurable on the
time scale of the experiment. Figure 2 contains the 452
amino acid sequence of TetC where the lines indicate all
peptides observed within the first 120 min of digestion
accounting for 57% sequence coverage. Proteolytic frag-
ments overlapping in amino acid sequence from 304–
328 and 364–376 aid in the interpretation of specific
amino acids affected by TetC-doxorubicin complex for-
mation.
MALDI MS analysis of the time resolved limited
proteolysis experiments (every 10 min for 120 min) are
represented in Figures 3 and 4 which show MALDI
mass spectra of the peptide map generated by a trypsin
digest at 60 and 100 min of TetC and the TetC-doxoru-
bicin complex, respectively. These mass spectra are
typical of the ten spectra obtained for each respective
digest time. Quenching the tryptic digest with acid and
Figure 3. MALDI-TOF mass spectrum of a (a) 60 min tryptic digest and (b) 100 min tryptic digest of
TetC.
Figure 4. MALDI-TOF mass spectrum of a (a) 60 min tryptic digest and (b) 100 min tryptic digest of
a solution containing 1:10 molar ratio of TetC:doxorubicin.
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addition of MALDI matrix is likely to dissociate any
specific non-covalent interactions remaining in solution
after digestion; therefore, detection of doxorubicin
bound to a tryptic peptide or TetC by MALDI MS is
improbable. The peptide maps of TetC and the TetC-
doxorubicin complex in the mass spectra of Figures 3
and 4 are qualitatively similar, which is expected be-
cause of the small interaction interface and lack of
global protein conformation change in the TetC-doxo-
rubicin complex. However, careful inspection of the
MALDI mass spectra reveals significant differences in
the rate of proteolysis at several amino acids. For
example, in the proteolysis of the TetC-doxorubicin
complex relative to TetC there is a reduction in the
relative ion abundance of tryptic peptides at m/z 1135.5,
863.5, 676.4, and 841.5. Figure 5a shows the statistical
representation of the percent relative ion abundance
versus proteolysis time for the peptide at m/z 1135.5
[amino acids (a.a.) D351–R360]. From 20 to 100 min this
peptide is lower in abundance in TetC-doxorubicin
complex; at 110 and 120 min, the relative ion abundance
is within experimental error in both proteolysis exper-
iments. Similar rates of digestion are observed for m/z
Figure 6. Space-filling molecular representation of TetC where
the amino acids highlighted in yellow correspond to the tryptic
peptides of lower abundance in the TetC-doxorubicin complex
relative to TetC, including ions at m/z 1135.5 (a.a. 351–360), 863.5
(a.a. 305–311), 676.4 (a.a. 312–316), and 841.5 (a.a. 299–304).
Figure 7. Space-filling molecular representation of TetC where
the amino acids highlighted in yellow correspond to the individ-
ual amino acids of the peptides highlighted in Figure 6 that are
responsible for the decrease of the peptide ion abundance. Doxo-
rubicin is suggested to block trypsin from cleaving at amino acid
R360, K311 and R305.
Figure 5. Comparison of percent relative ion abundance versus
digest time for various peptide ions observed in the TetC and the
TetC-doxorubicin tryptic digests. (a) Peptide ion at m/z 1135.5
consistently has a decreased ion abundance in the TetC-doxoru-
bicin complex from 20 to 100 min. Three other peptides, m/z 863.5,
676.4, and 841.5, follow a similar pattern. (b) Peptide ion at m/z
1909.9 consistently has an increased ion abundance in the TetC-
doxorubicin complex from 20 to 100 min. Five additional peptides,
m/z 1291.7, 1419.9, 2065.9, 1520.9, and 1582.8, follow a similar
pattern. (c) The ion abundance for peptide ion at m/z 1735.9 in the
TetC-doxorbucin complex is within experimental error of the
same ion in TetC. The same is true for 19 other peptides observed.
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863.5 (a.a. R305–K311), m/z 676.4 (a.a. F312–R316), and
m/z 841.5 (a.a. L299–R304). The fact that the rates of
proteolysis of these four peptides is reduced in the
complex for the first 100 min, but rebounds to equal that
of the ligand-free protein at 110 min suggests that
understanding the initial rates of proteolysis at the most
accessible sites is critical because at longer times of
digestion, the protease can access sites buried into the
tertiary structure. One interpretation for the observa-
tion of peptides having a decreased abundance in the
complex is that doxorubicin reduces the ability of the
protease to access specific amino acids, such as K298,
R304, R305, K311, R316, K350, or R360, by physically
blocking these sites. Another possible interpretation is
that upon binding, doxorubicin induces a conforma-
tional change that alters the tertiary structure enough to
reduce the rate of proteolysis at a given site.
Another observation in the time resolved limited
proteolysis of the TetC-doxorubicin complex relative to
the ligand-free protein is an increase in relative ion
abundance of six peptides including m/z 1520.9 (a.a.
R305–R316), 1582.8 (a.a. R316–K328), 2065.9 (a.a. N281–
K298), 1291.7 (a.a. V364–K375), 1419.7 (a.a.V364–K376),
and 1909.9 (a.a. L335–K350). Interestingly, the peptide
ion at at m/z 1520.9 is a peptide with a missed cleavage
site at amino acid K311. Because peptides containing
R305–K311 and F312–R316 are less abundant in the
complex, but R305–R316 is more abundant implies that
the binding of doxorubcin interferes with trypsin’s
ability to access amino acids K311 and F312. A space-
filling molecular representation of the X-ray crystal
structure of TetC (Figure 6) aids in the visualization of
the peptides of decreased abundance in the complex.
The yellow highlights, with exception of amino acids
426 and 430, correspond to the four peptides of reduced
ion abundance in the TetC-doxorubicin complex. The
yellow highlighted amino acids in Figure 7 correspond
to the peptide’s terminal amino acids that could be
blocked by doxorubicin, including D369-I361, L310-
I313, and R304-L306. If we compare the computation-
ally predicted doxorubicin binding site (Figure 8) with
the peptides that show a decreased abundance, it is
consistent that doxorubicin blocks trypsin’s ability to
access R360 and K311, identifying one binding site. The
reduced ion abundance of peptide L299-R304 has two
possible explanations. One, doxorubicin has an addi-
tional binding site. This would corroborate the ESI MS
data in Figure 1 that suggests doxorubicin has multiple
binding sites at a 1:10 molar ratio. (Note, no attempt
was made to design ESI experiments for characterizing
ligand binding specificity). Or two, the specific binding
of doxorubicin to the site near amino acids D369-I361
and L310-I313 induces a conformational change that
reduces trypsin’s ability to cleave at amino acids K298
or R304.
Surprisingly, the other five peptides exhibiting an
increased relative ion abundance in the complex flank
the regions where a decrease in ion abundance is
observed. Figure 5b contains the statistical representa-
tion of the percent relative ion abundance for peptide
ion at m/z 1909.9. (It is important to note that out of the
29 peptides observed in 120 min of the trypsin digest, 19
of the peptides did not exhibit a change in ion abun-
dance from the ligand free protein to the complex as
shown in Figure 5c for the peptide ion at m/z 1735.9).
The fragment ion at m/z 1909.9 (a.a. L335–K350) is first
observed in the digest of the complex at 20 min, but is
not observed until 40 min in the digest of TetC and
remains at an elevated abundance in the TetC-doxoru-
bicin complex until 110 min of digestion. This indicates
Figure 8. The computationally predicted doxorubicin binding site.
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some amino acids become more accessible to trypsin
upon complex formation. An interpretation of an in-
crease in trypsin’s ability to cleave at specific amino
acids in the complex may suggest that doxorubicin
induces a tertiary structure realignment near the bind-
ing site. The amino acids highlighted in red in Figure 9,
with the exception of 426 and 430, are the remaining
five peptides showing an increased ion abundance in
the complex. The peptide ions containing amino acids
L335–K350 and V364–K376 are at the N- and C-terminal
ends, respectively, of the peptide ion (a.a.351–R360) that
had a reduced ion abundance in the TetC-doxorubicin
complex. Thus, these regions of increased ion abun-
dance border regions on TetC where a decrease in ion
abundance is observed, suggesting that doxorubicin
does not merely bind to the surface of TetC, but rather
doxorubicin forces the protein to react, whereby the
amino acids adjacent to the binding site “pucker”
around doxorubicin, opening up the structure for tryp-
sin to attack other sites more readily.
Conclusions
The time resolved limited proteolysis experiments fol-
lowed by MALDI MS analysis of the resulting peptide
maps demonstrated herein are the first accounts of MS
providing a rapid method for characterizing binding
sites and protein conformation changes in protein-small
molecule non-covalent complexes with M dissociation
constants. Up to this point X-ray crystallography and
NMR have been the only analytical tools used to probe
protein structural motifs in small molecule binding
events. Although the methods outlined in this paper for
a TetC-doxorubicin complex do not obtain the atomic-
level resolution of X-ray crystallography or NMR, they
do provide a high throughput tool with relatively low
Figure 9. Space-filling molecular representation of TetC where the amino acids highlighted in red
correspond to the tryptic peptides of increased abundance in the TetC-doxorubicin complex relative
to TetC, including ions at m/z 1909.9 (a.a. 335–350), 1291.7 (a.a. 364–375), 1419.9 (a.a. 364–376), and
1582.8 (a.a. 316–328).
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amounts of protein (4 M) for determining ligand
binding sites and changes in protein structure induced
by the non-covalent binding of small molecule ligands.
Trypsin was the enzyme used to define the time re-
solved limited proteolysis experimental protocol, how-
ever, we have preliminary results using other proteases
including Asp-N, Glu-C, and Lys-C that corroborate the
doxorubicin binding site and conformational changes
induced by binding.
There are several cases where the methods described
herein could be critical to investigators designing drugs
to inhibit protein function or designing molecules for
molecular recognition applications. One such case is the
need to determine small molecule binding sites where
the binding site is experimentally unknown but the
X-ray crystal structure of the protein is known as was
the case detailed in this paper. This method could also
prove useful in determining whether protein conforma-
tional changes induced by one ligand binding event
inhibits binding of another ligand to another site. For
example, we have preliminary evidence to suggest that
when doxorubicin binds to TetC, the conformational
change of TetC reduces the ability of TetC to recognize
gangliosides GD1b, the TetC receptor on the cell surface
of neurons.
The strengths of the time resolved limited proteoly-
sis lie in the ability to identify ligand binding sites one
ligand at a time in a relatively high throughput and
automated manner using MALDI TOF MS; however
there are several weaknesses to this method. The choice
of MALDI TOF MS and the inherent error of 20% in
ion abundance measurements could affect experiment
outcome and data interpretation. For example, there
may be more proteolyitic fragments that have subtle
changes in abundance that are not accounted for using
MALDI. For the TetC-doxorubicin complex, a 1:10 mo-
lar ratio was required to observe a change in the rate of
proteolysis using MALDI, yet it is possible that this
molar ratio could be reduced if the error in ion abun-
dance measurements could be reduced. Reducing the
ion abundance measurement errors could be accom-
plished by implementing LC/MS analysis of the time
resolved proteolytic fragments. Reducing the molar
ratio closer to 1:1 could also be critical in determining
binding specificity of which the methods as outlined
within the manuscript do not attempt to understand. In
addition, if a ligand does not directly interact with
amino acids consistent with a protease’s specificity,
then no binding site information can be obtained.
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